Roseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease

Aker University Hospital, Oslo, Norway.
Scandinavian Journal of Gastroenterology (Impact Factor: 2.36). 10/2004; 39(10):1017-20. DOI: 10.1080/00365520410007971
Source: PubMed
1 Follower
62 Reads
  • Source
    • "In the last decade, there have been discussions among clinicians about the use of fecal calprotectin in IBD diagnostics: as a surrogate marker for endoscopic activity, as a predictor of relapse or as a sorting marker between irritable bowel syndrome and IBD [10] [11] [12]. Some studies have shown that fecal calprotectin can be used as a marker for mucosal healing in IBD patients [5]. Summerton et al. [2] showed that the calprotectin level is elevated in inflammation and cancer, but it is not a helpful marker in the differentiation between these disorders. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective: Fecal calprotectin is a noninvasive marker of intestinal inflammation used to distinguish between functional and organic bowel diseases and to evaluate disease activity among patients with Inflammatory Bowel Disease (IBD). The goal of this study was to compare three different ELISA tests measuring calprotectin in their accuracy to detect IBD and to distinguish between IBD patients with active or inactive disease. Material and methods: This study includes in total 148 fecal samples, 96 from patients with a previously confirmed IBD diagnosis and 52 from healthy controls, aged from 25 to 86 and 18 to 67 years, respectively. Disease activity in the patients was established using the following clinical activity indices: the Simple Clinical Colitis Activity Index (SCCAI), the Harvey Bradshaw Index (HBI) and the Modified Pouchitis Disease Activity Index (MPDAI). Three ELISA calprotectin tests (EK-CAL, CALPRO and HK325) were performed on fecal specimens and results compared. Results: The CALPRO calprotectin ELISA test was shown to have the best specificity of 96% compared to the HK325 and the EK-CAL calprotectin ELISA tests with 28% specificity and 74% specificity, respectively. A significant correlation between clinical activity indices and fecal calprotectin was found in patients with ulcerative colitis (p < 0.05***) and in patients with an ileoanal pouch (p < 0.05), but not in patients with Crohn's disease (p = 0.11). Conclusion: The CALPRO ELISA test performed best in measuring calprotectin in feces.
    Scandinavian Journal of Gastroenterology 09/2015; 51(2):1-7. DOI:10.3109/00365521.2015.1081399 · 2.36 Impact Factor
    • "FC seems to be a useful surrogate marker to estimate IBD activity because it correlates with clinical assessment and endoscopic findings in both CD [6] [7] and UC [8]. Data on FC as a surrogate marker of mucosal healing are also emerging in IBD patients [9] [10]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Faecal calprotectin levels correlate with inflammation in inflammatory bowel disease. We evaluated the role of faecal calprotectin after anti-Tumour Necrosis Factor alpha induction in inflammatory bowel disease patients to predict therapeutic effect at one year. Methods: Faecal calprotectin levels were measured in stools of 63 patients before and after induction of anti-Tumour Necrosis Factor alpha therapy. Clinical activity, measured by clinical indices, was assessed before and after biologic treatment. Clinical responders after induction were included in the study and colonoscopy was performed before and after one year of treatment to assess mucosal healing. Results: 63 patients (44 Crohn's disease, 19 ulcerative colitis) were prospectively included (41.2% males, mean age at diagnosis 33 years). A sustained clinical response during the first year was observed in 57% of patients; median faecal calprotectin was 106 mu g/g after induction versus 308 mu g/g pre-induction (p < 0.0001). Post-induction faecal calprotectin was significantly lower in responders versus non-responders (p = 0.0002). Post-induction faecal calprotectin had 83% sensitivity and 74% specificity (cut-off <= 168 mu g/g) for predicting a sustained clinical response at one year (p = 0.0001); also, sensitivity was 79% and specificity 57% (cut-off <= 121 mu g/g) for predicting mucosal healing (p = 0.0001). Conclusions: In inflammatory bowel disease faecal calprotectin assay after anti-Tumour Necrosis Factor alpha induction can be used as a marker to predict sustained clinical response and mucosal healing at one year.
    Digestive and Liver Disease 08/2014; 46(11). DOI:10.1016/j.dld.2014.07.013 · 2.96 Impact Factor
  • Source
    • "Calprotectin decreases significantly after IFX treatment for 12 weeks, and it correlated with endoscopic index of severity (CDEIS) (r = 0.561, P = 0.03) [54]. Røseth et al. show that fecal calprotectin level correlated with endoscopic mucosal healing [55]. A meta-analysis focusing on fecal calprotectin in IBD relapse shows that the sensitivity and specificity when predicting the relapse are 78% and 73%, separately [56]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Inflammatory bowel disease (IBD) is a chronic disease mostly involved with intestine with unknown etiology. Diagnosis, evaluation of severity, and prognosis are still present as challenges for physicians. An ideal biomarker with the characters such as simple, easy to perform, noninvasive or microinvasive, cheap, rapid, and reproducible is helpful for patients and clinicians. Currently biomarkers applied in clinic include CRP, ESR, pANCA, ASCA, and fecal calprotectin. However, they are far from ideal. Lots of studies are focused on seeking for ideal biomarker for IBD. Herein, the paper reviewed recent researches on biomarkers of IBD to get advances of biomarkers in inflammatory bowel disease.
    Disease markers 05/2014; 2014:710915. DOI:10.1155/2014/710915 · 1.56 Impact Factor
Show more